Co‑culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274

Tomizawa,Minoru; Shinozaki,Fuminobu; Motoyoshi,Yasufumi; Sugiyama,Takao; Yamamoto,Shigenori; Ishige,Naoki

doi:10.3892/br.2014.361

November-December 2014 Volume 2 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-December 2014 Volume 2 Issue 6

Full Size Image

Article

Co‑culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274

Authors:
- Minoru Tomizawa
- Fuminobu Shinozaki
- Yasufumi Motoyoshi
- Takao Sugiyama
- Shigenori Yamamoto
- Naoki Ishige
View Affiliations / Copyright

Affiliations: Department of Gastroenterology, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Radiology, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Neurology, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Rheumatology, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Pediatrics, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Neurosurgery, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan
Pages: 799-803
|
Published online on: September 10, 2014

https://doi.org/10.3892/br.2014.361
Expand metrics +

Abstract

Mesenchymal‑epithelial transition factor (c‑Met) is a receptor that binds to the hepatocyte growth factor and is upregulated in hepatocellular carcinoma (HCC). The anti‑tumor effects of (3Z)‑N‑(3‑chlorophenyl)‑3‑({3,5‑dimethyl‑4‑[(4‑methyl-piperazin‑1‑yl)carbonyl]‑1H‑pyrrol‑2‑yl}methylene)‑N‑me-thyl‑2‑oxo‑2,3‑dihydro‑1H‑indole‑5‑sulfonamide (SU11274), a c‑Met inhibitor, were investigated in the present study. HCC cells (HLE, HLF, PLC/PRL/5, Hep3B, Huh‑6 and HepG2) and human umbilical vein endothelial cells (HUVECs) were used. Quantitative polymerase chain reaction was performed to detect the expression level of c‑Met in HCC and HUVECs, and cyclin D1 in HCC. The 3‑(4,5‑dimethylthiazol‑2‑yl)‑5‑(3‑car-boxymethoxyphenyl)‑2‑(4‑sulfophenyl)‑2H‑tetrazolium inner salt assay was performed to assess the proliferation of the HCC cells and HUVECs cultured with SU11274. Co‑culture of HLF or PLC/PRL/5 cells and HUVECs was established as an in vitro model of HCC tissues. The expression levels of c‑Met in HLE, HLF, PLC/PRL/5, Hep3B, Huh‑6 and HepG2, adult healthy liver and HUVECs were 4.43±0.50, 1.61±0.18, 3.70±0.08, 0.81±0.18, 6.60±1.29, 1.06±0.35, 1.00±0.09 and 88.8±17.3 (mean ± standard deviation), respectively. SU11274 (30 µM) suppressed the proliferation of HLF, PLC/PRL/5 and HUVECs to 11.0±9.4, 46.5±30.7 and 29.4±5.0%, respectively. SU11274 (30 µM) decreased the expression levels of cyclin D1 in HLF and PLC/PRL/5 cells to 45.1±11.6 and 30.1±10.3%, respectively. SU11274, at a concentration of 30 µM damaged the morphology of the co‑cultures of HLF or PLC/PRL/5 cells with HUVECs and all the cells died. c‑Met is highly expressed in HUVECs and HCC cells, but not in Hep3B. At a 30‑µM concentration, SU11274 suppresses the proliferation of HLF, PLC/PRL/5 and HUVECs. SU11274 (30 µM) damages the co‑cultures of HLF or PLC/PRL/5 cells with HUVECs.

View Figures

View References

1	Lencioni R, Petruzzi P and Crocetti L: Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 30:3–11. 2013. View Article : Google Scholar
2	Kim HY and Park JW: Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 3:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
3	Tomizawa M, Kondo F and Kondo Y: Growth patterns and interstitial invasion of small hepatocellular carcinoma. Pathol Int. 45:352–358. 1995. View Article : Google Scholar : PubMed/NCBI
4	Miyahara K, Nouso K, Morimoto Y, et al: Okayama Liver Cancer Group: Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. Br J Cancer. 109:2072–2078. 2013. View Article : Google Scholar : PubMed/NCBI
5	Xie B, Wang DH and Spechler SJ: Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci. 57:1122–1129. 2012. View Article : Google Scholar : PubMed/NCBI
6	Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S and Nakajima K: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 99:159–165. 2008.PubMed/NCBI
7	Hu H, Duan Z, Long X, et al: Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS One. 9:e966202014. View Article : Google Scholar
8	Nishikawa H, Takeda H, Tsuchiya K, et al: Japanese Red Cross Liver Study Group: Sorafenib therapy for BCLC stage B/C hepatocellular carcinoma; clinical outcome and safety in aged patients: a multicenter study in Japan. J Cancer. 5:499–509. 2014. View Article : Google Scholar
9	Organ SL and Tsao MS: An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 3(Suppl 1): S7–S19. 2011. View Article : Google Scholar : PubMed/NCBI
10	Grigioni WF, Fiorentino M, D’Errico A, et al: Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology. 21:1543–1546. 1995.PubMed/NCBI
11	Kang GH, Lee BS, Lee ES, Kim SH, Lee HY and Kang DY: Prognostic significance of p53, mTOR, c-Met, IGF-1R, and HSP70 overexpression after the resection of hepatocellular carcinoma. Gut Liver. 8:79–87. 2014. View Article : Google Scholar : PubMed/NCBI
12	Scagliotti GV, Novello S and von Pawel J: The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 39:793–801. 2013. View Article : Google Scholar : PubMed/NCBI
13	Mughal A, Aslam HM, Sheikh A, Khan AM and Saleem S: c-Met inhibitors. Infect Agent Cancer. 8:132013. View Article : Google Scholar
14	Inagaki Y, Qi F, Gao J, et al: Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends. 5:52–56. 2011. View Article : Google Scholar : PubMed/NCBI
15	Dang Y, Luo D, Rong M and Chen G: Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One. 8:e610542013. View Article : Google Scholar : PubMed/NCBI
16	Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M and Yoshida T: Insulin-like growth factor I receptor involvement in proliferation of NOR-P1 cells in serum-free media. J Cell Biochem. 113:2714–2720. 2012. View Article : Google Scholar : PubMed/NCBI
17	Tomizawa M, Shinozaki F, Motoyoshi Y, et al: Niclosamide suppresses hepatoma cell proliferation via the Wnt pathway. Onco Targets Ther. 6:1685–1693. 2013. View Article : Google Scholar : PubMed/NCBI
18	Harrington LS, Sainson RC, Williams CK, et al: Regulation of multiple angiogenic pathways by DII4 and Notch in human umbilical vein endothelial cells. Microvasc Res. 75:144–154. 2008. View Article : Google Scholar : PubMed/NCBI
19	Hu SY, Duan HF, Li QF, et al: Hepatocyte growth factor protects endothelial cells against gamma ray irradiation-induced damage. Acta Pharmacol Sin. 30:1415–1420. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Co‑culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles